IBO_OUT_1 [2025-03-21 13:46:19 -0400] 2175 Bytes | 587 tokens | Cum: 587 tkns (7.34% of 8k)
==========================================================================

Alright, let’s light it up, because it's 1:46:17 PM on Fri Mar 21, 2025 -0400, and I'm charging into Impact BioMedical (IBO), popping from 2.08 to 4.2206. Is this our star stock of the day, or just a quick blip on the radar? I've got the scoop—time to analyze!

Here's the first list of news for Impact BioMedical:

C1 - Feb-26-25 08:30AM - Impact Biomedical Inc. Announces Acquisition of Celios , Protecting People, Plants, and Animals from the World's Most Dangerous Pathogens With Clean-Room Air Quality
C2 - Feb-26-25 08:30AM 08:30AM - DSS, Inc. Announces Sale of Celios® to Impact BioMedical, Streamlining Portfolio for Strategic Growth
C3 - Jan-23-25 04:30PM - Impact BioMedical Inc. to Present at The Microcap Conference
C4 - Nov-19-24 08:00AM - Impact BioMedical Inc. Issues Shareholder Letter Highlighting Recent Achievements and Strategic Vision
C5 - Nov-18-24 07:00AM - Impact BioMedical Inc. (NYSEAmerican: IBO): Targeting Chronic Diseases with Patented Breakthroughs
C6 - Nov-11-24 07:30AM - Positioned for Growth: Impact BioMedical Inc.'s (NYSEAmerican: IBO) Push into Cancer and Immune Health
C7 - Oct-15-24 06:00AM - Impact BioMedical Inc. Announces Issuance of Canadian Patent for Linebacker Technology Targeting Inflammatory Disease
C8 - Oct-07-24 08:30AM - Impact BioMedical Inc. (NYSE American: IBO) Announces IPO Participation with Strong Support from Partners and Affiliates

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Impact BioMedical (IBO)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

IBO_OUT_3 [2025-03-21 13:46:22 -0400] 1039 Bytes | 295 tokens | Cum: 884 tkns (11.05% of 8k)
==========================================================================

Showing C1 (chunk 1 of 4): C1:
**Impact Biomedical Inc. Announces Acquisition of Celios , Protecting People, Plants, and Animals from the World's Most Dangerous Pathogens With Clean-Room Air Quality**
Date: Feb-26-25 08:30AM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/02/26/3032920/0/en/Impact-Biomedical-Inc-Announces-Acquisition-of-Celios-Protecting-People-Plants-and-Animals-from-the-World-s-Most-Dangerous-Pathogens-With-Clean-Room-Air-Quality.html

February 26, 2025 08:30 ET| Source:IMPACT BIOMEDICAL INCIMPACT BIOMEDICAL INC

HOUSTON, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, today announced the acquisition of Celios®, a pioneering air purification technology company, in a strategic, all equity transaction valued at approxi

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

IBO_OUT_5 [2025-03-21 13:46:23 -0400] 1045 Bytes | 217 tokens | Cum: 1103 tkns (13.79% of 8k)
==========================================================================

Showing C1 (chunk 2 of 4): mately $1.15 million. This acquisition aligns with Impact Biomedical’s focused roll-up strategy, expanding its portfolio with cutting-edge solutions that will generate immediate revenue while reinforcing its commitment to human health and wellness.

Celios® brings advanced air purification capability, featuring design, system, and method patents issued in the U.S. and other countries with exclusivity through 2043. It delivers "virtually clean room" air quality through novel U.S. manufactured filter technology, which is highly effective, yet portable with an easy-to-use design.

"The acquisition of Celios® marks a significant milestone in our strategic growth plan," said Frank D. Heuszel, CEO of Impact Biomedical. "By integrating Celios’® proven air purification technology into our portfolio, we are expanding our offerings of innovative health and wellness solutions. This transaction unde

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

IBO_OUT_7 [2025-03-21 13:46:25 -0400] 985 Bytes | 312 tokens | Cum: 1417 tkns (17.71% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-21T17:05:38Z - 12 Health Care Stocks Moving In Friday's Intraday Session - GlucoTrack (NASDAQ:GCTK), CervoMed (NASD...
A2 - 2025-03-21T14:14:00Z - Dow Tumbles Over 400 Points; Nike Shares Dip After Q3 Results - Damon (NASDAQ:DMN), Allurion Technol...
A3 - 2025-03-21T13:00:00Z - Pre-market Movers: ALUR, IBO, PNBK, RNAZ, DSS....
A4 - 2025-03-21T12:10:22Z - 12 Health Care Stocks Moving In Friday's Pre-Market Session - Benitec Biopharma (NASDAQ:BNTC), Artiv...
A5 - 2025-03-21T10:21:07Z - Why Ouster Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket - AuthID (NAS...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

IBO_OUT_9 [2025-03-21 13:46:27 -0400] 1038 Bytes | 319 tokens | Cum: 1738 tkns (21.73% of 8k)
==========================================================================

Showing A1 (chunk 1 of 4): A1:
**12 Health Care Stocks Moving In Friday's Intraday Session - GlucoTrack (NASDAQ:GCTK), CervoMed (NASDAQ:CRVO)**Date: 2025-03-21Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/insights/movers/25/03/44440699/12-health-care-stocks-moving-in-fridays-intraday-sessionGainers Impact BioMedical IBO stock increased by 98.1% to $4.12 during Friday's regular session. The company's market cap stands at $47.4 million. TransCode Therapeutics RNAZ stock moved upwards by 60.9% to $1.24. Galecto GLTO shares increased by 40.09% to $5.8. The market value of their outstanding shares is at $7.6 million. As per the press release, Q4 earnings came out 2 days ago. Regencell Bioscience RGC stock increased by 30.36% to $58.67. The market value of their outstanding shares is at $763.4 million. Tonix Pharmaceuticals TNXP stock moved upwards by 26.71% to $23

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

IBO_OUT_11 [2025-03-21 13:46:28 -0400] 968 Bytes | 285 tokens | Cum: 2025 tkns (25.31% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-02-26T13:30:00Z - Impact Biomedical Inc. Announces Acquisition of Celios®, "Protecting People, Plants, and Animals from the World's Most Dangerous Pathogens With Clean-Room Air Quality"
B2 - 2024-12-12T20:56:00Z - Contractor Wins Prestigious Award for Exquisite Ornamental Staircase
B3 - 2024-10-25T11:00:00Z - ImPact Biotech to Present Updated Interim Phase 3 Data from ENLIGHTED Study of Padeliporfin VTP in Low Grade UTUC at EMUC 2024
B4 - 2024-10-15T10:00:00Z - Impact BioMedical Inc. Announces Issuance of Canadian Patent for Linebacker™ Technology Targeting Inflammatory Disease
B5 - 2024-09-17T15:29:05Z - Impact BioMedical Inc. Announces the Closing of its Initial Public Offering

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

IBO_OUT_13 [2025-03-21 13:46:31 -0400] 848 Bytes | 200 tokens | Cum: 2227 tkns (27.84% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Impact Biomedical Inc. Announces Acquisition of Celios®, "Protecting People, Plants, and Animals from the World's Most Dangerous Pathogens With Clean-Room Air Quality"**Date: Unknown DateSource: Unknown SourceURL: https://www.benzinga.com/pressreleases/25/02/g43971463/impact-biomedical-inc-announces-acquisition-of-celios-protecting-people-plants-and-animals-from-thImpact Biomedical Inc. has acquired Celios®, a pioneering air purification technology company, in a strategic all-equity transaction. The acquisition aligns with Impact Biomedical's strategy to expand its portfolio with cutting-edge solutions that generate immediate revenue and reinforce its commitment to human health and wellness.

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

IBO_OUT_15 [2025-03-21 13:46:33 -0400] 1093 Bytes | 299 tokens | Cum: 2581 tkns (32.26% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-01-29 8-K Item 7.01 Regulation FD Disclosure

Frank D. Heuszel, the Companys Chf Exec Off, provided certain investor information, commencing on January 29, 2025. The slide package prepared by the Company for use in connection with these presentations is furnished herewith as Ex...

S2 - 2025-01-29 8-K Item 7.01 Regulation FD Disclosure

Frank D. Heuszel, the Companys Chf Exec Off, provided certain investor information, commencing on January 29, 2025. The slide package prepared by the Company for use in connection with these presentations is furnished herewith as Ex...

S3 - 2024-11-12 10-Q Impact BioMedical Inc and Subsidiaries

Condensed Cons Balance Sheets

September 30, 2024

(unaudited)

December 31, 2023 ASSETS Curr assets: Cash and cash equiv $ 2,668,000 $ 1,000 A/R, net - 128,000 Curr portion of notes receivable 142...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

IBO_OUT_17 [2025-03-21 13:46:40 -0400] 1038 Bytes | 316 tokens | Cum: 2899 tkns (36.24% of 8k)
==========================================================================

Showing S3 (chunk 1 of 6): S3:
Impact BioMedical Inc and Subsidiaries

Condensed Consolidated Balance Sheets

September 30, 2024

(unaudited)

December 31, 2023 ASSETS Current assets: Cash and cash equivalents $ 2,668,000 $ 1,000 Accounts receivable, net - 128,000 Current portion of notes receivable 142,000 203,000 Prepaid expenses and other current assets 365,000 - Total current assets 3,175,000 332,000 Property, plant and equipment, net 282,000 287,000 Notes receivable 59,000 - Goodwill 25,093,000 25,093,000 Other intangible assets, net 18,086,000 18,921,000 Total assets $ 46,695,000 $ 44,633,000 LIABILITIES AND STOCKHOLDERS EQUITY Current liabilities: Accounts payable $ 1,001,000 $ 832,000 Accrued expenses and deferred revenue 102,000 230,000 Current portion note payable, related party 35,000 12,074,000 Total current liabilities 1,138,000 13,136,000 Long-term portion note payable, related party 7,971,000

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

IBO_OUT_19 [2025-03-21 13:46:52 -0400] 3826 Bytes | 1048 tokens | Cum: 4085 tkns (51.06% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+----------------------+-----------------------+-----------------------+-------------------------+-------------------+
| Volume: 109,787,765 | SMA50: 160.69% | Market Cap: 49.33M | Option/Short: No / No | Sales past 5Y: 0.00% | Sales Surprise: - |
+---------------------+----------------------+-----------------------+-----------------------+-------------------------+-------------------+
| Avg Volume: 546.12K | SMA200: 123.06% | Shs Outstand: 11.50M | Short Float: 0.18% | Employees: - | EPS Surprise: - |
+---------------------+----------------------+-----------------------+-----------------------+-------------------------+-------------------+
| Rel Volume: 315.57 | Perf Week: 615.00% | Shs Float: 5.11M | Short Ratio: 0.02 | Debt/Eq: 0.26 | P/E: 48.04 |
+---------------------+----------------------+-----------------------+-----------------------+-------------------------+-------------------+
| RSI (14): 80.90 | Perf Month: 114.50% | Inst Own: 0.77% | Short Interest: 0.01M | Sales Y/Y TTM: -100.00% | Earnings: - |
+---------------------+----------------------+-----------------------+-----------------------+-------------------------+-------------------+
| ATR (14): 0.66 | Perf Quarter: 89.82% | Insider Own: 55.61% | Beta: - | ROE: 4.01% | |
+---------------------+----------------------+-----------------------+-----------------------+-------------------------+-------------------+
| SMA20: 218.83% | Index: - | Insider Trans: -0.06% | Sales Q/Q: - | ROI: 2.95% | |
+---------------------+----------------------+-----------------------+-----------------------+-------------------------+-------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

[Company Financial Summary]
[Company Details]
Name: Impact BioMedical, Inc.
Market Cap: 40947177.427
Shares Outstanding: 11503955
Sector: PHARMACEUTICAL PREPARATIONS

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': 4241000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 4.13
Average Volume: 6174323.61
30-Day High: 4.13
30-Day Low: 0.53

[Detailed Financials: Q3 2024]
- Total Assets: $46,695,000.0
- Total Liabilities: $12,344,000.0
- Total Equity: $34,351,000.0
- Current Assets: $3,175,000.0
- Current Liabilities: $1,138,000.0

[Income Statement: Q3 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): 0.37

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $2,666,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

IBO_OUT_21 [2025-03-21 13:46:54 -0400] 676 Bytes | 167 tokens | Cum: 4488 tkns (56.10% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

IBO_IN_23 [2025-03-21 13:46:56 -0400] 126 Bytes | 29 tokens | Cum: 4545 tkns (56.81% of 8k)
==========================================================================

====================================
[2025-03-21 10:46:56] # Analysis Completed
Elapsed Time: 39.08 seconds